ORIC Pharmaceuticals, Inc. (ORIC) short interest & options flow
NASDAQORIC Pharmaceuticals heads into its November 13 earnings date with a rare combination: a fresh analyst upgrade, declining short interest, and a stock that has given back 6% over the past month despite a broadly constructive clinical story. The most newsworthy development this week is on the Street. JP Morgan's Anupam Rama raised his price target on ORIC to $26 from $23 this…
ORIC put/call ratio surges to 0.1874, a 4.2 standard deviations above the 20-day mean of 0.0922—the most bearish options sentiment in months. Stock down 21.6% in one month on Tazverik withdrawal concerns, despite analyst consensus of "Buy" with $20.36 target.
- Market cap
- $968M
- Next earnings
- 13 Nov 2026
Key data as of 5 Nov 2026
ORIC news and analysis
RSSNo long-form analysis yet for ORIC. Pulse alerts and the live data picture are available on ORTEX.
Open ORIC on ORTEX →Want the live picture for ORIC?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ORIC — free to start on ORTEX.
Sign up for free →Open ORIC on ORTEX